Tositumomab: Difference between revisions
From Proteopedia
Jump to navigationJump to search
David Canner (talk | contribs) No edit summary |
David Canner (talk | contribs) No edit summary |
||
| Line 2: | Line 2: | ||
{| class="wikitable" border="1" width="52%" style="text-align:center" | {| class="wikitable" border="1" width="52%" style="text-align:center" | ||
|- | |- | ||
! colspan="5" align="center"| Anti-CD20 Monoclonal Antibody [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmacokinetics]] | ! colspan="5" align="center"| Anti-CD20 Monoclonal Antibody [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmacokinetics]] <ref>GlaxoSmithKline: Study No.: Hx-CD20-402</ref> | ||
|- | |- | ||
! Parameter | ! Parameter | ||
| Line 12: | Line 12: | ||
! [[Pharmaceutical_Drugs#Tmax|T<sub>max</sub>]] (hr) | ! [[Pharmaceutical_Drugs#Tmax|T<sub>max</sub>]] (hr) | ||
! Tositumomab | ! Tositumomab | ||
! | ! 7.6 | ||
! Rituximab | ! Rituximab | ||
! Ibritumomab | ! Ibritumomab | ||
| Line 18: | Line 18: | ||
! [[Pharmaceutical_Drugs#Cmax|C<sub>max</sub>]] (ng/ml) | ! [[Pharmaceutical_Drugs#Cmax|C<sub>max</sub>]] (ng/ml) | ||
! Tositumomab | ! Tositumomab | ||
! | ! 167000 | ||
! Rituximab | ! Rituximab | ||
! Ibritumomab | ! Ibritumomab | ||
| Line 35: | Line 35: | ||
|- | |- | ||
! [[Pharmaceutical_Drugs#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr) | ! [[Pharmaceutical_Drugs#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr) | ||
! | ! 64.8 | ||
! | ! 68 | ||
! Rituximab | ! Rituximab | ||
! Ibritumomab | ! Ibritumomab | ||
| Line 42: | Line 42: | ||
! [[Pharmaceutical_Drugs#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr) | ! [[Pharmaceutical_Drugs#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr) | ||
! Tositumomab | ! Tositumomab | ||
! | ! 32939000 | ||
! Rituximab | ! Rituximab | ||
! Ibritumomab | ! Ibritumomab | ||
|- | |- | ||
! [[Pharmaceutical_Drugs#Clearance_.28Cl.29|Clearance]] (L/h) | ! [[Pharmaceutical_Drugs#Clearance_.28Cl.29|Clearance]] (L/h) | ||
! | ! .078 | ||
! | ! .017 | ||
! Rituximab | ! Rituximab | ||
! Ibritumomab | ! Ibritumomab | ||
| Line 60: | Line 60: | ||
! Dosage (mg) | ! Dosage (mg) | ||
! Tositumomab | ! Tositumomab | ||
! | ! 500 (4th Infusion) | ||
! Rituximab | ! Rituximab | ||
! Ibritumomab | ! Ibritumomab | ||
Revision as of 07:04, 6 December 2010
Pharmacokinetics
| Anti-CD20 Monoclonal Antibody Pharmacokinetics [1] | ||||
|---|---|---|---|---|
| Parameter | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
| Tmax (hr) | Tositumomab | 7.6 | Rituximab | Ibritumomab |
| Cmax (ng/ml) | Tositumomab | 167000 | Rituximab | Ibritumomab |
| Bioavailability (%) | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
| Protein Binding (%) | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
| T1/2 (hr) | 64.8 | 68 | Rituximab | Ibritumomab |
| AUC (ng/ml/hr) | Tositumomab | 32939000 | Rituximab | Ibritumomab |
| Clearance (L/h) | .078 | .017 | Rituximab | Ibritumomab |
| IC50 (nM) | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
| Dosage (mg) | Tositumomab | 500 (4th Infusion) | Rituximab | Ibritumomab |
| Metabolism | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
- ↑ GlaxoSmithKline: Study No.: Hx-CD20-402
